YOYoungman Oh

Youngman Oh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Youngman Oh has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Ho-Seong Kim

    Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea

    3 shared publications
  • Aki Harada

    Virginia Commonwealth Univ, Dept Pathol, Coll Med, Richmond, VA 23298 USA

    2 shared publications
  • Dae-Yeol Lee

    The §Department of Pathology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298

    2 shared publications
  • Jinfeng Han

    The §Department of Pathology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298

    2 shared publications
  • JungHyun Kim

    Department of Pediatrics, Institute of Endocrinology, Yonsei University College of Medicine, Seoul, Korea

    2 shared publications
  • Lathika Mohanraj

    Department of Pathology, Virginia Commonwealth University, Richmond, VA, USA

    2 shared publications

Latest Publications

  • Open Access

    IGFBP-3 Inhibits Cytokine-Induced Insulin Resistance and Early Manifestations of Atherosclerosis

    by Lathika Mohanraj, Ho-Seong Kim, Wei Li, Qing Cai, Ki Eun Kim, Hye-Jung Shin, Yong-Jae Lee, Woo Jung Lee, Jung Hyun Kim, Youngman Oh

    Metabolic syndrome is associated with visceral obesity, insulin resistance and an increased risk of cardiovascular diseases. Visceral fat tissue primarily consists of adipocytes that secrete cytokines leading to a state of systemic inflammation in obese conditions. One of the IGF-independent functions of IGFBP-3 is its role as an anti-inflammatory molecule. Our study in obese adolescents show a decrease in total IGFBP-3 levels and increase in proteolyzed IGFBP-3 in circulation when compared to their normal counterparts and establishes a positive correlation between IGFBP-3 proteolysis and adiposity parameters as well as insulin resistance. In human adipocytes, we show that IGFBP-3 inhibits TNF-α-induced NF-κB activity in an IGF-independent manner, thereby restoring the deregulated insulin signaling and negating TNF-α-induced inhibition of glucose uptake. IGFBP-3 further inhibits TNF-α, CRP and high glucose-induced NF-κB activity in human aortic endothelial cells (HAECs) and subsequently suppresses monocyte adhesion to HAEC through the IGFBP-3 receptor. In conclusion, these findings suggest that reduced levels of IGFBP-3 in circulation and reduced expression of IGFBP-3 in macrophages in obesity may result in suppression of its anti-inflammatory functions and therefore IGFBP-3 may present itself as a therapeutic for obesity-induced insulin resistance and for events occurring in the early stages of atherosclerosis.


  • Insulin-Like Growth Factor-Binding Protein-3 Mediates High Glucose-Induced Apoptosis by Increasing Oxidative Stress in Proximal Tubular Epithelial Cells

    by Eun-Gyong Yoo, Woo Jung Lee, Jung Hyun Kim, Hyun-Wook Chae, Se Eun Hyun, Duk Hee Kim, Ho-Seong Kim, Youngman Oh

    IGF-binding protein-3 (IGFBP-3) is the major circulating carrier protein for IGF, and also acts as a potent antiproliferative agent in various cell types. Recently, IGFBP-3 was reported to mediate high glucose-induced apoptosis in mesangial cells and podocytes. In this study, we investigated the role of IGFBP-3 in high glucose-induced apoptosis in proximal tubular epithelial cells (PTEC). Expression of IGFBP-3 protein and mRNA in a porcine PTEC line (LLC-PK1 cells) was measured after exposure to either standard (5.5 mM) or high-glucose (30 mM) medium. We quantified apoptosis after treatment with small interfering RNA against IGFBP-3 (siRNA:IGFBP-3) in high-glucose medium or in cells that overexpressed IGFBP-3. Oxidative stress was measured in high-glucose medium, in the presence of siRNA:IGFBP-3, or in IGFBP-3-overexpressing cells. IGFBP-3 protein and mRNA expression in LLC-PK1 cells was higher in high-glucose medium than in standard-glucose medium. Exposure to high-glucose medium increased apoptosis, and high-glucose-induced apoptosis was abolished by siRNA:IGFBP-3. IGFBP-3 overexpression induced apoptosis in LLC-PK1 cells. Both high-glucose medium and IGFBP-3 overexpression increased reactive oxygen species, and siRNA:IGFBP-3 reduced this increase. Antioxidant treatment decreased IGFBP-3 expression and apoptosis, whereas oxidative stress from hydrogen peroxide increased IGFBP-3 expression, suggesting that oxidative stress increases IGFBP-3 expression. Our results suggest that increased IGFBP-3 expression by high glucose mediates high-glucose-induced apoptosis in PTEC. Increased oxidative stress from high glucose enhances IGFBP-3 expression, inducing apoptosis. Increased expression of IGFBP-3 by high glucose induces additional oxidative stress, which may result in amplification of hyperglycemic damage.


  • Open Access

    Insulin-like Growth Factor-binding Protein-3 (IGFBP-3) Blocks the Effects of Asthma by Negatively Regulating NF-κB Signaling through IGFBP-3R-mediated Activation of Caspases

    by Yong-Chul Lee, Sherryline Jogie-Brahim, Dae-Yeol Lee, Jinfeng Han, Aki Harada, Liam J. Murphy, Youngman Oh


  • Open Access

    Identification of a Novel Cell Death Receptor Mediating IGFBP-3-induced Anti-tumor Effects in Breast and Prostate Cancer

    by Angela R. Ingermann, Yong-Feng Yang, Jinfeng Han, Aki Mikami, Amanda E. Garza, Lathika Mohanraj, Lingbo Fan, Michael Idowu, Joy L. Ware, Ho-Seong Kim, et al.


  • Impact of IGFBP-3 in Human Cardiovascular Diseases.

    by L Mohanraj, Youngman Oh

    Obesity is a health abnormality that increases the risk and incidence of developing atherosclerosis primarily in populations of developed countries including United States. Studies emphasize that obesity has a strong association with cardiovascular diseases (CVD). Visceral obesity is obesity due to increased deposition of fat in the abdominal viscera and is the initial stage for CVD. Chronic inflammation of the adipose tissue leads to release of cytokines and inflammatory factors that play a key role in promoting CVD. Tumor necrosis factor α (TNF-α) is a cytokine produced by adipose tissue, endothelial cells and macrophages that play a major role in inflammatory response and monocyte recruitment to early lesions of atherosclerosis. TNF-α is known to be a potent activator of nuclear factor kappa B (NF-κB), a family of transcription factors involved in the atherosclerotic process. NF-κB regulates adhesion molecules like ICAM and VCAM and chemokines such as monocyte chemo-attractant protein (MCP-1) and IL-8 that contribute towards CVD. Another well characterized marker of cardiovascular risk is C-reactive protein (CRP). CRP activates NF-κB activity that further regulates the expression of MCP-1 and VCAM. Insulin resistance induced by high glucose and atherosclerosis are tightly intertwined disorders. Hyperglycemia induces damage to the endothelium through activation of NF-κB pathway amongst others. Insulin-like Growth Factor Binding Protein-3 (IGFBP-3), a major binding protein of IGF modulates IGF by regulating IGF binding to its receptors. It also contributes to the pathophysiology of a variety of disease states in an IGF independent manner. With respect to IGF-I/IGF-I receptor independent actions of IGFBP-3, it is known to interfere and inhibit the NF-κB pathway. Since NF-κB plays a significant role in the progression of atherosclerosis, we explored the role of IGFBP-3 as a therapeutic target in cardiovascular diseases. In our experiments using human aortic endothelial cells (HAEC), we demonstrated that IGFBP-3 inhibits the elevated NF-κB activity induced by treatment with factors involved in CVD such as TNF-α, CRP and high glucose. This subsequently led to the inhibition of NF-κB regulated proteins such as ICAM, VCAM and MCP-1 at mRNA and protein levels. Taken together, our findings strongly suggest that IGFBP-3 may prevent/inhibit the initiation/progression of CVD and pose as an ideal therapeutic candidate for obesity induced CVD. Nothing to Disclose: LM, YO